Results 21 to 30 of about 138,095 (212)

Potential Effects of Silymarin and Its Flavonolignan Components in Patients with β-Thalassemia Major: A Comprehensive Review in 2015

Advances in Pharmacological Sciences, 2016
Major β-thalassemia (β-TM) is one of the most common inherited hemolytic types of anemia which is caused as a result of absent or reduced synthesis of β-globin chains of hemoglobin. This defect results in red blood cells lysis and chronic anemia that can
Hadi Darvishi Khezri, Ebrahim Salehifar, Mehrnoush Kosaryan, Aily Aliasgharian, Hossein Jalali, Arash Hadian Amree   +5 more
doaj   +1 more source

Phosphaturia in Thalassemia

Pediatrics, 1976
Thirteen phosphorus balances were performed in four thalassemic children aged 6 to 10 years. No correlation was found between phosphorus intake and serum level or between phosphorus intake and net absorption. There was a positive correlation among daily phosphorus intake, net absorption, and 24-hour urinary excretion.
Lapatsanis, P., Sbyrakis, S., Vertos, C., Karaklis, B. A., Dosiadis, S.   +4 more
openaire   +3 more sources

Let’s talk about thal: How communication can improve quality of life

Thalassemia Reports, 2018
In many parts of the world, research, improved technology, and better medicine have enabled people with thalassemia to live longer. It is tragic that due to global disparity in healthcare, in areas of the world where thalassemia is most prevalent, the ...
Laurice M. Levine
doaj   +1 more source

Ferritin thresholds for cardiac and liver hemosiderosis in β-thalassemia patients: a diagnostic accuracy study

Scientific Reports, 2022
Ferritin is frequently used to screen some dire consequences of iron overload in β-thalassemia patients. The study aimed to define the best cutoff point of ferritin to screen for cardiac and liver hemosiderosis in these cases.
Hadi Darvishi-Khezri, Aily Aliasgharian, Mohammad Naderisorki, Mehrnoush Kosaryan, Mobin Ghazaiean, Hanie Fallah, Mohammad Zahedi, Hossein Karami   +7 more
doaj   +1 more source

Bromhexine is a potential drug for COVID-19; From hypothesis to clinical trials

Вопросы вирусологии, 2022
COVID-19 (novel coronavirus disease 2019), caused by the SARS-CoV-2 virus, has various clinical manifestations and several pathogenic pathways. Although several therapeutic options have been used to control COVID-19, none of these medications have been ...
S. Bahadoram, B. Keikhaei, M. Bahadoram, M.-R. Mahmoudian-Sani, S. Hassanzadeh, A. Saeedi-Boroujeni, K. Alikhani   +6 more
doaj   +1 more source

PREGNANCY IN THALASSEMIA

Mediterranean Journal of Hematology and Infectious Diseases, 2019
Therapeutic advances, including the availability of oral iron chelators and new non-invasive methods for early detection and treatment of iron overload, have significantly improved the life expectancy and quality of life of patients with thalassemia, with a consequent increase in their reproductive potential and desire to have children.
Raffaella Origa, Federica Comitini
openaire   +4 more sources

Chronic hyperplastic anemia as an independent risk factor for atherosclerotic lesions: a lesson from thalassemia intermedia [PDF]

, 2010
Introduction. Cardiovascular involvement represents a well-known complication and the primary cause of mortality, both in transfusion-dependent beta thalassemia major (β-TM) and in transfusion-independent beta thalassemia intermedia (β-TI ...
Pier Luigi Cocco, Alessandra Spiga, Fabrizio Angius, Stefania Vacquer, Maria Eliana Lai, Antonella Mandas, Maria Paola Carta, Sandra Dessi   +7 more
core  

The shortcut strategy for beta thalassemia prevention

Hematology Reports, 2018
We propose antenatal blood tests using high-resolution DNA melting (HRM) analysis for beta thalassemia mutation detection after hemoglobin A2 estimation as a modified strategy for the identification of beta thalassemia at-risk couples.
Narutchala Suwannakhon, Khajohnsilp Pongsawatkul, Teerapat Seeratanachot, Khwanruedee Mahingsa, Arunee Pingyod, Wanwipa Bumrungpakdee, Torpong Sanguansermsri   +6 more
doaj   +1 more source

Mithramycin encapsulated in polymeric micelles by microfluidic technology as novel therapeutic protocol for beta-thalassemia [PDF]

, 2012
This report shows that the DNA-binding drug, mithramycin, can be efficiently encapsulated in polymeric micelles (PM-MTH), based on Pluronic® block copolymers, by a new microfluidic approach.
Carugo, D, Zhang, Xunli, Nastruzzi, C, Capretto, Lorenzo, Hill, M, Hill, Martyn, Gambari, Roberto, Capretto, L, Zhang, X, Mazzitelli, S, Brognara, E, Nastruzzi, Claudio, Brognara, Eleonora, Carugo, Dario, Gambari, R, Lampronti, I, Mazzitelli, Stefania, Lampronti, Ilaria   +17 more
core   +1 more source

Whole exome sequencing and rare variant association study to identify genetic modifiers, KLF1 mutations, and a novel double mutation in Thai patients with hemoglobin E/beta-thalassemia

, 2023
Clinical manifestations of patients with Hemoglobin E/beta-thalassemia vary from mild to severe phenotypes despite exhibiting the same genotype. Studies have partially identified genetic modifiers.
Kittiphong Paiboonsukwong (5774672), Nawaporn Tansiri (14836554), Surasak Sawatnatee (14836557), Wikanda Pholmoo (14836590), Supawee Saengboon (13010646), Kanyaporn Charoenprasert (14836566), Wichuda Thamprasert (14836569), Nisachon Khorwanichakij (14836581), Chayamon Takpradit (14836560), Narumol Nolwachai (14836572), Wannaphorn Rotchanapanya (6280742), Saranya Pongudom (14836563), Wanlapa Rattanasawat (14836575), Noppadol Siritanaratkul (6413990), Bhoom Suktitipat (202143), Putchong Saetow (14836584), Chanin Limwongse (145689), Krittichat Kamjornpreecha (14836587), Manop Pithukpakorn (744798), Boonyanuch Dujjawan (14836593), Yingyong Chinthammitr (11857510), Busakorn Sae-Aeng (14836578), Chattree Hantaweepant (14836551)   +22 more
core   +1 more source